Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors.
Efforts to enhance the antileukemic properties of arsenic trioxide are clinically relevant and may lead to the development of new therapeutic approaches for the management of certain hematological malignancies. We provide evidence that concomitant treatment of acute myeloid leukemia (AML) cells or chronic myeloid leukemia (CML) cells with resveratrol potentiates arsenic trioxide-dependent induction of apoptosis. Importantly, clonogenic assays in methylcellulose demonstrate potent suppressive effects of the combination of these agents on primitive leukemic progenitors derived from patients with AML or CML. Taken together, these findings suggest that combinations of arsenic trioxide with resveratrol may provide an approach for targeting of early leukemic precursors and, possibly, leukemia initiating stem cells.
Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Chicago, IL USA.
Edward J
EJ
Wu
Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Chicago, IL USA; Division of Hematology/Oncology; Department of Medicine; Feinberg School of Medicine; Northwestern University; Chicago, IL USA; Department of Medicine; Jesse Brown VA Medical Center; Chicago, IL USA.
Dennis J
DJ
Goussetis
Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Chicago, IL USA; Division of Hematology/Oncology; Department of Medicine; Feinberg School of Medicine; Northwestern University; Chicago, IL USA.
Elspeth
E
Beauchamp
Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Chicago, IL USA.
Ewa M
EM
Kosciuczuk
Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Chicago, IL USA; Division of Hematology/Oncology; Department of Medicine; Feinberg School of Medicine; Northwestern University; Chicago, IL USA; Department of Medicine; Jesse Brown VA Medical Center; Chicago, IL USA.
Jessica K
JK
Altman
Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Chicago, IL USA; Division of Hematology/Oncology; Department of Medicine; Feinberg School of Medicine; Northwestern University; Chicago, IL USA; Department of Medicine; Jesse Brown VA Medical Center; Chicago, IL USA.
Elizabeth A
EA
Eklund
Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Chicago, IL USA; Division of Hematology/Oncology; Department of Medicine; Feinberg School of Medicine; Northwestern University; Chicago, IL USA; Department of Medicine; Jesse Brown VA Medical Center; Chicago, IL USA.
Leonidas C
LC
Platanias
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000494:pharmacology*; D001343:Autophagy / Q000187:drug effects; D045744:Cell Line, Tumor; D004357:Drug Synergism; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000378:metabolism* / Q000473:pathology; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism* / Q000473:pathology; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000473:pathology; D010087:Oxides / Q000494:pharmacology*; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D013267:Stilbenes; D000077185:Resveratrol; D000077237:Arsenic Trioxide
apoptosis; arsenic trioxide; autophagy; myeloid leukemia